You Are Invited to a CME/CPE/CE Teleconference
Introduction
Multiple sclerosis (MS) is a progressive, autoimmune, neurologic disease that affects approximately 400,000 people in the United States. Recent findings indicate that early diagnosis of MS in patients is vital to achieving improved clinical outcomes. Although magnetic resonance imaging techniques have been routinely used for definitively diagnosing MS patients, these techniques are continuously being improved upon, allowing earlier identification of the disease; thus, neurologists should be updated.
Early diagnosis enables early treatment. It is essential that neurologists understand the benefits of early treatment of MS with immunomodulatory drugs in slowing the progression of the disease and improving patient outcomes. Recent focus has turned to the involvement of axonal loss as an immediate and major problem in MS. Therefore, novel and emerging therapeutic strategies are being designed to target neuroprotection and repair mechanisms.
Expert thought leaders will utilize a case-based format and present the newest evidence-based standards for definitively diagnosing MS. They will also analyze the most recent clinical trial data and provide up-to-date practice recommendations for the treatment and management of patients with MS, as well as highlight emerging therapies that can improve compliance and clinical outcomes in those with this debilitating disease.
Target Audience
This teleconference series will be accredited for neurologists and neurology physician assistants, nurse practitioners, and nurses who care for patients with MS.
This complimentary activity will consist of a teleconference with a guidebook as well as discussion and question-and-answer sessions.